Nakamura, George

Case under preparation for upcoming board

Case under preparation for upcoming board

Case under preparation for upcoming board

58-year-old with borderline resectable pancreatic head adenocarcinoma (SMV abutment <180 degrees), CA 19-9 1,200 U/mL, KRAS G12D. Neoadjuvant regimen selection: FOLFIRINOX vs. gemcitabine/nab-paclitaxel considering ECOG 1, mild biliary obstruction (stented), and BRCA wild-type status. Discuss resectability reassessment timeline.

Vascular involvement reassessment after neoadjuvant therapy — surgical candidacy.

Borderline resectable disease — neoadjuvant FOLFIRINOX vs. gemcitabine/nab-paclitaxel.

Borderline resectable disease — neoadjuvant FOLFIRINOX vs. gemcitabine/nab-paclitaxel.

Borderline resectable disease — neoadjuvant FOLFIRINOX vs. gemcitabine/nab-paclitaxel.

BRCA2 mutation — maintenance olaparib eligibility after platinum-based first-line.

Borderline resectable disease — neoadjuvant FOLFIRINOX vs. gemcitabine/nab-paclitaxel.

Gemcitabine vs. FOLFIRINOX in adjuvant setting for resected pancreatic cancer with CA 19-9 elevation.

BRCA2 mutation — maintenance olaparib eligibility after platinum-based first-line.

Locally advanced unresectable — SBRT vs. conventional fractionation after induction chemotherapy.

Vascular involvement reassessment after neoadjuvant therapy — surgical candidacy.

Locally advanced unresectable — SBRT vs. conventional fractionation after induction chemotherapy.